2/26
08:00 am
iova
Iovance Biotherapeutics to Present at Upcoming Conferences
Medium
Report
Iovance Biotherapeutics to Present at Upcoming Conferences
2/25
10:58 am
iova
Iovance Biotherapeutics (IOVA) had its price target raised by Barclays PLC from $10.00 to $11.00. They now have an "overweight" rating on the stock.
High
Report
Iovance Biotherapeutics (IOVA) had its price target raised by Barclays PLC from $10.00 to $11.00. They now have an "overweight" rating on the stock.
2/25
09:24 am
iova
Iovance Biotherapeutics (IOVA) had its price target lowered by Chardan Capital from $17.00 to $16.00. They now have a "buy" rating on the stock.
Medium
Report
Iovance Biotherapeutics (IOVA) had its price target lowered by Chardan Capital from $17.00 to $16.00. They now have a "buy" rating on the stock.
2/25
08:12 am
iova
Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
2/25
08:00 am
iova
Iovance Biotherapeutics (IOVA) was upgraded by Citizens Jmp from "market perform" to "outperform". They now have a $5.00 price target on the stock.
Low
Report
Iovance Biotherapeutics (IOVA) was upgraded by Citizens Jmp from "market perform" to "outperform". They now have a $5.00 price target on the stock.
2/24
04:53 pm
iova
Iovance Biotherapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/24
03:51 pm
iova
Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade) [Seeking Alpha]
Neutral
Report
Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade) [Seeking Alpha]
2/24
01:06 pm
iova
Iovance Biotherapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/24
09:32 am
iova
Iovance Biotherapeutics Says Potential Sarcoma Therapy Shows 50% Response Rate in Pilot Clinical Trial [Yahoo! Finance]
High
Report
Iovance Biotherapeutics Says Potential Sarcoma Therapy Shows 50% Response Rate in Pilot Clinical Trial [Yahoo! Finance]
2/24
07:36 am
iova
Iovance Biotherapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
High
Report
Iovance Biotherapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
2/24
07:00 am
iova
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
High
Report
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
2/24
07:00 am
iova
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
High
Report
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
2/20
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2/19
10:09 am
iova
Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds? [Yahoo! Finance]
Medium
Report
Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds? [Yahoo! Finance]
2/17
09:02 pm
iova
Iovance Biotherapeutics Inc. (IOVA) Builds Momentum With New Trial Data [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics Inc. (IOVA) Builds Momentum With New Trial Data [Yahoo! Finance]
2/11
04:27 pm
iova
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 [Yahoo! Finance]
2/11
04:05 pm
iova
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
Medium
Report
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
2/7
09:31 am
iova
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Low
Report
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Volatility [Yahoo! Finance]
2/6
11:12 am
iova
Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure [Yahoo! Finance]
2/5
05:15 pm
iova
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Medium
Report
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
2/5
08:04 am
iova
Iovance Biotherapeutics (NASDAQ:IOVA) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Iovance Biotherapeutics (NASDAQ:IOVA) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/16
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
1/16
05:31 am
iova
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed [Yahoo! Finance]
1/15
11:53 pm
iova
Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns [Yahoo! Finance]
1/15
02:36 pm
iova
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory [Yahoo! Finance]